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ABSTRACT A critical appraisal and clinical application of Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. 
Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007 Mar;45(3):666-74. doi: 10.1002/hep.21553 
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Clinical Context 
A 74 year-old Caucasian female with history significant for renal cell carcinoma status post right nephrectomy 
presented as a transfer from an outside hospital with three weeks of pruritus, jaundice, elevated liver function 
tests (LFTs), and elevated bilirubin (total and direct). Two months prior, results from a routine surveillance CT 
abdomen/pelvis revealed a pancreatic head mass as well as a severely distended gallbladder with multiple stones 
and intrahepatic biliary dilation. Under our care she underwent endoscopic retrograde cholangiopancreatography 
(ERCP) and an endoscopic ultrasound (EUS), revealing compression of the major papilla from a mass found in the 
distal common bile duct and pancreatic head. Cannulation could not be performed and she was admitted for 
percutaneous transhepatic cholangiography (PTC) drain placement with Interventional Radiology. Patient 
remained stable with no signs of cholangitis, and the drain was placed two days later. Bilirubin and liver function 
tests trended down following drain placement. Biopsy results were consistent with metastatic renal cell carcinoma, 
clear cell type. The patient preferred to follow up with oncology closer to home and was discharged with the drain 
to be removed in six to eight weeks. Throughout her hospitalization, the patient was asymptomatic besides 
unbearable pruritus and jaundice. She received treatment with the PTC drain and anti-histamines, however the 
pruritus persisted to discharge. Her main concern was always, “Doctor, what can I take to stop this itching?” 
Addressing the patient’s concern began with understanding the standards of care for cholestatic pruritus. An 
UpToDate article titled Pruritus associated with cholestasis outlined multiple medication options. For moderate to 
severe pruritus, trials of cholestyramine, rifampin, naltrexone, or sertraline were recommended.5 Of the options 
serotonin was of particular interest because in addition to pruritus, the patient also described multiple weeks of 
depressive symptoms and worsening mood with her recent diagnosis. Since sertraline has known effective anti-
depressive properties, the team wanted to investigate the efficacy of the medication’s anti-pruritic effects in order 
to reduce pill burden. 
Clinical Question 
Do selective serotonin-reuptake inhibitors provide a clinically significant reduction in symptoms for patients with cholestatic 
pruritus? 
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Research Article 
Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. 
Hepatology. 2007 Mar;45(3):666-74. doi: 10.1002/hep.21553 
Related Literature 
A PubMed search with keywords “cholestatic pruritus” and “treatment” and “SSRI” sorted by the most recent feature yielded 17 
results. Of those results, six were relevant to the clinical question. The Cochrane Review evaluated the evidence on multiple 
pharmacological interventions for pruritus in palliative care patients and concluded that SSRI’s are a viable option for reduction of 
pruritus symptoms.7 This and the second systematic review were utilized to evaluate for further relevant citations.3,7 Of the 
remaining four citations, Mayo proved to be the strongest and most applicable trial to the patient clinical scenario discussed. 
The Zyclizc study8 was excluded due to poor clinical fit and study duration. Zyclicz included palliative care patients with pruritus of 
varying natures, including both non-malignant and malignancies of multiple origins. Of the 26 patients, only three had pruritus of 
cholestatic origin. Additionally, the Zyclicz study was of shorter duration compared to Mayo: one week per each arm of the 
randomized crossover versus six weeks in Mayo. Mayo’s study also analyzed a secondary outcome measure and discussion about 
depression with SSRI use, while Zyclicz did not.4,8 The Browning trial was excluded for two reasons: inadequate patient 
demographics and retrospective nature of study.1 Only primary biliary cholangitis (PBC) was included in Browning’s study, while PBC, 
primary sclerosing cholangitis (PSC), and Hepatitis C Virus (HCV) cirrhosis were included in Mayo’s study. Therefore, Mayo’s study 
better reflects the breadth of cholestatic disease. Mayo’s study was also selected because a placebo-controlled double blind 
crossover study provides more strength than a retrospective analysis of patients who used sertraline “at some point.”1,4 Finally, 
Unotoro was excluded due to the low number of patients included in analysis.6 
Critical Appraisal 
This research is a two part clinical trial, including an initial dose escalation (Part A) followed by a placebo-controlled double blind 
crossover study (Part B). Part A was designed to determine the optimal sertraline dose for participation in part B and to identify 
tolerability. Part B was designed to determine the efficacy of sertraline as a first-line treatment for cholestatic pruritus. Prior to Part 
A, patients received a two-week washout of all anti-pruritic medications. In Part A, all participants were evaluated with a starting 
dose of 25 mg sertraline daily. Every four weeks the dose was titrated by 25 mg to one of three endpoints: resolution of pruritus, 
intolerable side effects, or no further experienced benefits from increased dose. Once reached, the optimal dose was continued for 
a total of six weeks. Prior to Part B, all patients underwent a two-week washout period. In Part B patients were randomly assigned to 
double blind treatment with either placebo or sertraline All patients underwent six weeks of treatment with either placebo or 
optimal dose sertraline as determined in Part A. Treatment was followed by a four week washout period and cross over to other 
therapy for an additional six weeks. Primary endpoints in treatment were improvements in subjective itching in terms of course, 
duration, and distribution. Secondary endpoints included tolerability and depression.  
Patients were recruited from UT Southwestern Medical Center and included in the study if they had stable or slowly progressive liver 
disease and at least three months of pruritus. Exclusion criteria included subjects currently taking another antidepressant, opioid-
containing medication, ondansetron, corticosteroids, octreotide, phenothiazine, or anti-retroviral for viral hepatitis. Current use of 
another anti-pruritic medication was not an exclusion criterion as long as subjects underwent a two-week washout period. The 
described patient met both inclusion and exclusion criteria. Additionally, the patient reflects demographics features of the trial 
subjects: (83% female and 50 % white in the randomized crossover).  However, while all subjects included in the study have pruritus 
of cholestatic origin, none had the similar mechanism of obstructive cholestasis secondary to malignancy. 
Significant improvements in pruritic symptoms were found in both the open-label (53%) and randomized crossover (33%), while no 
treatment successes were found in the placebo group. In fact, the placebo group experienced worsening of symptoms. Clinically 
significant improvement in pruritus was determined prior to start of the study as at least a 20% reduction in pruritus from baseline 
based on the visual analog scale. Additional outcomes included improvement in scratching lesions (83%) and symptoms of patients 
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with moderate to severe depression. Depressive symptoms were analyzed at each visit with the 30-item Inventory of Depressive 
Symptomatology Self-Report.  
Despite clinically significant improvement in symptoms, the trial had some limitations. The most significant limitation is the small 
subject size. Of the 38 subjects screened, 17 were excluded (most commonly for previous SSRI use), and of the 21 enrolled in Part A 
only 12 subjects completed Part B. High dropout rates were most commonly due to advancement of disease course or transplant. 
These high rates may have masked potential failures of treatment, influencing positive results. Any study with low number of 
participants raises the question of whether the study reflects and can be applied to the population at large. Additionally, the 
participants were recruited from one center, which may also limit the generalizability of the study to the population as a whole.  
Another weakness of the study was the subjective nature in which the data was collected. Pruritic symptoms were subjectively 
reported in daily itch journals using a visual analog scale with facial expressions as a guide. Use of a reporting with a 0-10 scale 
becomes problematic with a crossover study design. For example, a patient who was initially assigned to the sertraline group and 
received relief may report higher scores of pruritic symptoms while in the placebo group after washout. This subjective reporting 
may inflate the effect of sertraline. Similar assumptions can be made of the reporting and effect of depressive symptoms.  
One strength of the study includes the placebo-controlled double blind nature of Part B. However, the authors identified the 
inclusion of part A to have limited the effectiveness of the placebo group. Participants already underwent optimal treatment with 
sertraline prior to being randomized. Patients were familiar with their expected response to sertraline, defeating the purpose of 
randomization. The nature of the trial also allowed for establishment of multiple markers for evaluating improvement of pruritic 
symptoms. This offers strength over retrospective cohort studies, which would be unable to find multiple consistent markers of 
itching status. Lastly, one must consider the possible bias of the study as Dr. Rush disclaims that he has stock in the company Pfizer 
which is a producer of Zoloft (sertraline hydrochloride). 
This placebo-controlled double blind study meets criteria for level 2 evidence using the SORT criteria.2 
Clinical Application 
Clinicians will face patients similar to the clinical scenarios described above with the question of “What are my 
options for long term control of my itching symptoms?” Multiple management options exist for pruritus with 
different physiologic targets of action: histamine, bile acid, serotonin, etc. Serotonin reuptake inhibitors were 
selected for analysis due to desire for management of the above patient’s concomitant depression. Based on 
multiple different outcome measurements, this paper has shown sertraline to have some effectiveness as an 
option for cholestatic pruritus therapy, in addition to improvement in moderate to severe depressive symptoms4. 
This paper is valuable to patients and physicians because it additionally measured and acknowledged the use of 
sertraline for its antidepressant effects. As physicians it is our due diligence to reduce pill burden and search for 
opportunity to take advantage of medication side effect profiles. Therefore, sertraline can be considered as a 
treatment option for patients with cholestatic pruritus, particularly those with concomitant depression. The above 
patient was offered the option of sertraline for her pruritus and concomitant depression, due to the low risk 
profile of the medication. However, the patient elected to not begin any new medications on discharge, desiring to 
wait until she spoke with her oncologist outpatient. 
Take Home points: 
1. Multiple pharmacologic options exist for the management of cholestatic pruritus, including: anti-histamines, 
sertraline, cholestyramine, rifampin, and naltrexone. Sertraline can be considered with caution in patients 
with cholestatic pruritus and concomitant depression. 
2. While sertraline has been shown to have some effect as an option for cholestatic pruritus, the current data 
should be used with caution. Further, larger studies are required before definitive recommendations can be 
made. 
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3. Clinicians should always take into consideration the entire clinical picture and consider when patients may 
benefit from medication side effect profiles. 
4. While blinded placebo crossover studies have many strengths, the design itself creates a bias in results when 
patients are able to recognize differences in feeling or clinical results and figure out which group to which they 
were randomized. 
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